A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site
| Autor: | Kazuhiko Nakagawa, Nobuyuki Yamamoto, Naotoshi Sugimoto, Asuka Tsuya, Isao Goto, Shinya Ueda, Koji Matsumoto, Akihiro Tamiya, Takayasu Kurata, Masahiro Fukuoka, Isamu Okamoto, Daisuke Sakai |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Antimetabolites Antineoplastic medicine.medical_treatment Phases of clinical research Neutropenia Gastroenterology Tegafur Internal medicine medicine Carcinoma Humans Pharmacology (medical) Aged Pharmacology Cisplatin Aged 80 and over Chemotherapy business.industry Combination chemotherapy Middle Aged medicine.disease Surgery Drug Combinations Oxonic Acid Treatment Outcome Oncology Neoplasms Unknown Primary Female business Febrile neutropenia medicine.drug |
| Zdroj: | Investigational new drugs. 31(6) |
| ISSN: | 1573-0646 |
| Popis: | Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1–21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink